• The number of people aged 65 or older living with AD in the countries under study will increase by 45% over the forecast period, from 13.1 million in 2016 to 19 million in 2026.

Table of contents

  • Alzheimer's Disease - Epidemiology - Emerging Markets
    • Introduction
      • Key Findings
        • Overview
          • Total Prevalence of Alzheimer's Disease per 1,000 People Aged 65+ in 2016 and 2026
          • Relative Sizes of the Contributing Factors to the Trend in Total Prevalent Cases of Alzheimer's Disease over the Next Ten Years
          • Total Prevalent Cases of Alzheimer's Disease by Severity
      • Epidemiology Data
      • Methods
        • Total Incident Cases of Alzheimer's Disease
        • Total Prevalent Cases of Alzheimer's Disease
        • Total Prevalent Cases by Severity
        • Diagnosed Prevalent Cases of Alzheimer's Disease
        • Drug-Treated Prevalent Cases of Alzheimer's Disease by Severity
        • Total Prevalent Cases of Alzheimer's Disease by APOE e4 Status
        • Lifetime DALYs Gained
      • Reference Materials
        • Literature Review
          • Studies Included in the Analysis of Alzheimer's Disease
          • Studies Excluded from the Analysis of Alzheimer's Disease
        • Risk/Protective Factors
          • Risk/Protective Factors for Alzheimer's Disease
        • Bibliography

      Author(s): Nishant Kumar, MPH

      Nishant is a senior epidemiologist and head of oncology within the epidemiology team at Decision Resources Group. He also covers some CNS diseases, including Alzheimer’s disease and dementia. His key interests are developing interactive patient flows, and modelling disease progression to forecast commercially relevant drug-treatable incident and prevalent populations. Nishant also spends a lot of time collaborating with clients to help answer more specific questions through custom work and consulting projects.

      His qualifications include an MSc in Public Health with specialization in epidemiology and statistics from King’s College London, and a BSc in Medical Studies from the University of Birmingham.


      Related Reports

      Alzheimer's Disease - Landscape & Forecast - Disease Landscape & Forecast

      View Details

      Alzheimer's Disease | Disease Landscape and Forecast | G7 | 2020

      The Alzheimer’s disease (AD) market comprises a handful of symptomatic options that offer modest efficacy for a limited duration, leaving wide open the opportunity for more-effective alternatives—i...

      View Details

      Alzheimer's Disease - Epidemiology - Mature Markets

      DRG Epidemiology’s coverage of Alzheimer’s disease (AD) comprises epidemiological estimates of key...

      View Details